1. Home
  2. RLJ vs XERS Comparison

RLJ vs XERS Comparison

Compare RLJ & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ

RLJ Lodging Trust of Beneficial Interest $0.01 par value

HOLD

Current Price

$11.42

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.95

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLJ
XERS
Founded
2011
2005
Country
United States
United States
Employees
73
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RLJ
XERS
Price
$11.42
$6.95
Analyst Decision
Hold
Buy
Analyst Count
6
6
Target Price
$7.83
$10.83
AVG Volume (30 Days)
1.7M
1.6M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
7.26%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
$2.02
$34.37
Revenue Next Year
$2.54
$22.86
P/E Ratio
$188.67
$690.00
Revenue Growth
N/A
142.67
52 Week Low
$6.54
$4.52
52 Week High
$11.54
$10.08

Technical Indicators

Market Signals
Indicator
RLJ
XERS
Relative Strength Index (RSI) 81.95 65.21
Support Level $7.24 $6.86
Resistance Level N/A $7.14
Average True Range (ATR) 0.27 0.23
MACD 0.04 0.06
Stochastic Oscillator 95.32 86.92

Price Performance

Historical Comparison
RLJ
XERS

About RLJ RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: